一、本次限制性股票归属的决策程序及相关信息披露 证券代码：688331 证券简称：荣昌生物 公告编号：2025-048 港股代码：09995 港股简称：榮昌生物 荣昌生物制药（烟台）股份有限公司 2022 年 A 股限制性股票激励计划之 B 类权益预留授予 第一个归属期第一次归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 102,000股。 本次股票上市流通总数为102,000股。 本次股票上市流通日期为2025 年 11 月 17 日。 4、2022 年 12 月 28 日，公司召开 2022 年第二次临时股东大会、2022 年第一 次 A 股类别股东大会及 2022 年第一次 H 股类别股东大会，审议并通过了《关于< 荣昌生物制药（烟台）股份有限公司 2022 年 A 股限制性股票激励计划（草案）> 及其摘要的议案》《关于<荣昌生物制药（烟台）股份有限公司 2022 年 A 股限制性 股票激励计划实施考核管理办法>的 ...

Core Insights - The article discusses the recent financial performance of a company, highlighting significant revenue growth and strategic initiatives that have contributed to its success [1] Financial Performance - The company reported a revenue increase of 25% year-over-year, reaching $1.5 billion in the last quarter [1] - Net income rose to $300 million, reflecting a 15% increase compared to the previous year [1] Strategic Initiatives - The company has launched a new product line that is expected to capture a larger market share, contributing to future revenue growth [1] - Investments in technology and innovation have been prioritized, with a budget allocation of $200 million for R&D in the upcoming fiscal year [1] Market Position - The company has strengthened its position in the industry, now holding a 20% market share, up from 15% last year [1] - Competitive analysis indicates that the company is well-positioned against its main rivals, with a focus on customer satisfaction and service quality [1]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1]. Core Views - The report highlights a positive change in the specialty raw materials sector, recommending companies such as Aorite and Prolo Pharmaceuticals [1]. - The report suggests that the Q3 performance of raw material pharmaceutical companies has reached a bottom, indicating potential recovery in profitability as high-cost inventory is consumed [19][20]. Summary by Sections Investment Highlights - The recommended sub-industry rankings are: Innovative Drugs > Research Services > CXO > Traditional Chinese Medicine > Medical Devices > Pharmacies [3][12]. - Specific stock recommendations include: - From raw materials: Aorite, Qianhong Pharmaceutical - From Traditional Chinese Medicine: Zorui Pharmaceutical, Fangsheng Pharmaceutical, Dong'e Ejiao - From medical devices: United Imaging Healthcare, Yuyue Medical - From AI pharmaceuticals: Jingtai Holdings - From GLP-1 sector: Lianbang Pharmaceutical, Borui Pharmaceutical, Zhongsheng Pharmaceutical, and Innovent Biologics - From PD-1/VEGF dual antibodies: Sanofi Biopharmaceuticals, Kangfang Biologics, and Rongchang Biopharmaceuticals - From innovative drugs: Innovent Biologics, BeiGene, HengRui Medicine, Zai Lab, Baillie Tianheng, Kelun Pharmaceutical, Dize Pharmaceutical, and Haizheng Pharmaceutical [3][15]. Industry Trends - The A-share pharmaceutical index has seen a year-to-date increase of 18.2%, while the Hang Seng Biotechnology Index has increased by 76.6% [6][11]. - The report notes that the raw material pharmaceutical sector is under pressure due to high base effects and declining prices, with significant revenue impacts [19][20]. R&D Progress and Company Dynamics - Recent approvals include Novartis' radioligand therapy drug, which received dual indications for prostate cancer treatment [2]. - The report provides an overview of ongoing clinical trials and drug approvals, emphasizing the importance of innovation in the pharmaceutical sector [30]. Market Performance - The report indicates that the pharmaceutical sector has experienced adjustments, with notable stock performances including significant gains for companies like Hezhong China (+61%) and Wanze Shares (+30%) [11]. - The report also highlights the performance of various pharmaceutical stocks, noting both gains and losses in the market [16][17]. Raw Material Pricing Trends - The price of 6-APA has dropped significantly, from 370 RMB/kg in 2022 to 180 RMB/kg in October 2025, a decrease of 51% [23]. - The price of Amoxicillin has also decreased from 320 RMB/kg in January 2023 to 190 RMB/kg in October 2025, a decline of 41% [23]. Conclusion - The report suggests that as high-cost inventory is depleted, the gross margins for raw material producers are expected to improve, indicating a potential recovery in profitability for companies like Fuxiang Pharmaceutical and Lukang Pharmaceutical [19][23].

Core Insights - The article presents a ranking of 78 unprofitable biotechnology companies listed in Hong Kong, highlighting their market capitalizations and stock prices as of October 31, 2025 [1][2][3]. Market Capitalization Summary - The top three companies by market capitalization are: 1. 名要放田 (Ming Yao Fang Tian) with a market cap of HKD 286.26 billion 2. 信达生物 (Innovent Biologics) with a market cap of HKD 149.08 billion 3. 科伦博泰生物-B (Kintor Pharmaceutical) with a market cap of HKD 104.47 billion [1][2]. Price Performance Summary - The highest price increase for the year is observed in: 1. 北海康成-B (Beihai Kangcheng) with a price increase of 1381.20% 2. 药康安康 - B (Yao Kang An Kang) with a price increase of 1297.72% 3. 三叶草生物-B (San Ye Cao) with a price increase of 812.86% [3][4]. Additional Performance Insights - Other notable performers include: - 德棋医药-B (Deqi Pharmaceutical) with a 696.92% increase - 和铂失药-B (He Bo Shi Yao) with a 624.19% increase - 荣昌生物 (Rongchang Biologics) with a 525.00% increase [3][4]. Overall Trends - The article indicates a significant volatility in the biotechnology sector, with many companies experiencing substantial price fluctuations, reflecting investor sentiment and market dynamics [3][4].

Core Viewpoint - Rongchang Biological announced on November 7 that as of September 30, 2025, the total number of common stock shareholders is 15,267 [2] Summary by Category - **Company Information** - Rongchang Biological has reported a total of 15,267 common stock shareholders as of September 30, 2025 [2] - **Investor Communication** - The company responded to investor inquiries on its interactive platform regarding shareholder numbers [2]

Investment Rating - The industry investment rating is "Overweight" [6] Core Insights - Yum China reported Q3 2025 revenue of $3.2 billion, a year-on-year increase of 4%, and core operating profit of $399 million, up 8%, aligning with expectations [1][4] - The net new store openings for KFC and Pizza Hut reached a record high in Q3, with a total of 536 new stores, bringing the total to 17,514 [2][4] - Same-store sales for KFC increased by 2% year-on-year, while Pizza Hut saw a 1% increase, marking the 12th consecutive quarter of positive same-store sales growth [5] Summary by Sections Overseas Catering - Yum China achieved Q3 2025 revenue of $3.2 billion, a 4% increase year-on-year, and core operating profit of $399 million, an 8% increase, meeting expectations [1][4] - KFC and Pizza Hut net new store openings reached a record high in Q3, with 536 new stores added, totaling 17,514 stores [2][4] - KFC's same-store sales increased by 2% year-on-year, with transaction volume up 3% and average ticket price down 1% to 38 yuan [5] Overseas Pharmaceuticals - Rongchang Biologics reported a 42.3% year-on-year revenue increase in the first three quarters of 2025, reaching 1.72 billion yuan, with a net loss of 551 million yuan, narrowing by 48.6% [8] - In Q3, revenue grew by 33.1% year-on-year and 8.7% quarter-on-quarter, reaching 622 million yuan, with a net loss of 101 million yuan, narrowing by 65.2% year-on-year [8] - The company’s R&D expenses decreased by 22.8% year-on-year to 891 million yuan in the first three quarters [8] Overseas Education - The education sector's growth rate has bottomed out, with New Oriental's revenue growth accelerating due to its strong reputation [3] - The education index fell by 6.0% in the week of October 31 to November 6, underperforming the Hang Seng Index by 6.1 percentage points [15] - New Oriental's GMV on Douyin was approximately 170 million yuan for the week, with a daily average of 24.2 million yuan, reflecting a 2.7% week-on-week decline [16]

Investment Rating - The report maintains an "Overweight" rating for the overseas consumer services sector, indicating a positive outlook for the industry [1]. Core Insights - Yum China reported a revenue of $3.2 billion for Q3 2025, a year-on-year increase of 4%, with core operating profit rising by 8% to $399 million, aligning with expectations [1][4]. - The company achieved a record net store opening of 536 locations in Q3, bringing the total to 17,514 stores, with KFC and Pizza Hut expanding into over 310 and 170 new cities respectively [2][4]. - Same-store sales for KFC grew by 2% year-on-year, driven by a 3% increase in transaction volume, while Pizza Hut's same-store sales increased by 1% with a significant 17% rise in transaction volume [5]. Summary by Sections Overseas Consumer Services - Yum China accelerated its store opening pace in Q3 2025, achieving a total of 536 new stores, with KFC at 12,640 and Pizza Hut at 4,022 [2][4]. - The company has entered over 310 new cities for KFC and 170 for Pizza Hut in the past 12 months, with a total of approximately 2,500 and 1,000 cities served respectively [2][4]. - New store formats, such as KFC Coffee and KPRO, are expanding consumer engagement and market presence [2][4]. Overseas Pharmaceuticals - Rongchang Bio reported a 42.3% year-on-year revenue growth for the first three quarters of 2025, reaching 1.72 billion yuan, with a net loss of 551 million yuan, narrowing by 48.6% [9]. - The third quarter saw a revenue increase of 33.1% year-on-year, amounting to 622 million yuan, with a net loss of 101 million yuan, a significant reduction of 65.2% year-on-year [9]. - The company’s R&D expenses decreased by 22.8% year-on-year to 891 million yuan, while sales expenses increased by 32.1% to 823 million yuan, with a sales expense ratio decline of 3.7 percentage points to 47.8% [9]. Overseas Education - The education sector's growth has stabilized, with New Oriental experiencing a revenue acceleration driven by its strong brand reputation [16]. - The education index fell by 6.0% in the week of October 31 to November 6, underperforming the Hang Seng Index by 6.1 percentage points [16]. - New Oriental's GMV on Douyin was approximately 170 million yuan, with a daily average of 24.2 million yuan, reflecting a 2.7% week-on-week decline [17].

Core Viewpoint - Rongchang Biopharmaceuticals has experienced significant stock price fluctuations and changes in shareholder composition, reflecting its ongoing developments in the biopharmaceutical sector and market dynamics [1][3][4]. Financial Performance - As of September 30, 2025, Rongchang Biopharmaceuticals reported a revenue of 1.72 billion yuan, representing a year-on-year growth of 42.27% [3]. - The company recorded a net profit attributable to shareholders of -551 million yuan, which is a 48.60% increase compared to the previous period [3]. Stock Market Activity - On November 6, 2023, the stock price of Rongchang Biopharmaceuticals fell by 2.00%, trading at 90.16 yuan per share with a total market capitalization of 50.815 billion yuan [1]. - The stock has seen a year-to-date increase of 199.44%, with a recent 5-day increase of 1.69% and a 20-day decrease of 12.86% [1]. Shareholder Composition - As of September 30, 2025, the number of shareholders increased by 18.33% to 15,300, while the average number of circulating shares per person decreased by 15.54% to 10,639 shares [3]. - The top ten circulating shareholders include significant players such as Hong Kong Central Clearing Limited and Wanjiayouxuan, with notable changes in their holdings [4].

Core Viewpoint - Rongchang Biopharmaceuticals experienced a 5.21% decline in stock price, reaching 91.70 CNY per share, with a trading volume of 3.32 billion CNY and a turnover rate of 2.19%, resulting in a total market capitalization of 51.683 billion CNY [1] Company Overview - Rongchang Biopharmaceuticals, established on July 4, 2008, and listed on March 31, 2022, is located in the Yantai Free Trade Zone, Shandong, China. The company focuses on innovative biopharmaceuticals with a global perspective, specializing in antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies [1] - The company aims to discover, develop, and commercialize innovative first-in-class and best-in-class biopharmaceuticals, targeting significant diseases such as autoimmune diseases, tumors, and ophthalmic diseases, providing safe, effective, and accessible clinical solutions to meet unmet clinical needs [1] - The revenue composition of the company is as follows: 99.46% from product sales, 0.38% from material sales, and 0.16% from leasing services [1] Fund Holdings - Allianz Fund has a significant holding in Rongchang Biopharmaceuticals, with the Allianz China Select Mixed A Fund (021981) holding 73,600 shares, accounting for 3.33% of the fund's net value, making it the sixth-largest holding. The estimated floating loss today is approximately 370,900 CNY [2] - The Allianz China Select Mixed A Fund was established on September 3, 2024, with a current size of 186 million CNY. Year-to-date returns are 51.55%, ranking 773 out of 8,150 in its category; the one-year return is 32.76%, ranking 2,096 out of 8,043; and since inception, the return is 79.13% [2]

Core Viewpoint - Rongchang Biopharmaceuticals experienced a decline of 5.21% on November 5, with a stock price of 91.70 CNY per share and a total market capitalization of 51.683 billion CNY [1] Company Overview - Rongchang Biopharmaceuticals, established on July 4, 2008, and listed on March 31, 2022, is located in the Yantai Free Trade Zone, Shandong, China. The company focuses on innovative biopharmaceuticals, particularly in the fields of antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies [1] - The company aims to discover, develop, and commercialize innovative first-in-class and best-in-class biopharmaceuticals, targeting significant diseases such as autoimmune diseases, tumors, and ophthalmic diseases, to provide safe, effective, and accessible clinical solutions [1] - The revenue composition of the company is as follows: 99.46% from product sales, 0.38% from material sales, and 0.16% from leasing services [1] Fund Holdings - According to data, Huafu Fund has a significant holding in Rongchang Biopharmaceuticals, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) increasing its stake by 96,000 shares in the third quarter, bringing the total to 168,000 shares, which constitutes 9.1% of the fund's net value [2] - The fund has reported a floating loss of approximately 846,700 CNY as of the latest update [2] - The Huafu Health and Entertainment Flexible Allocation Mixed A Fund was established on August 4, 2015, with a current scale of 50.2705 million CNY. Year-to-date returns stand at 41.01%, ranking 1537 out of 8150 in its category, while the one-year return is 32.13%, ranking 2177 out of 8043 [2]